XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study

Completed

Conditions studied: Angioplasty, Chronic Coronary Occlusion, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis

In brief

This is a prospective, observational, single-arm, open-label, multicenter, postapproval registry study in China. The purpose of this study is to: * Evaluate the continued safety and effectiveness of the XIENCE V EECSS in a cohort of real-world patients receiving the XIENCE V EECSS during commercial use * Evaluate patient compliance to dual antiplatelet therapy (DAPT)

Key facts

Study ID

NCT01249027

Run by

Abbott Medical Devices

People needed

2605

Starts

2010-11-01

Expected to finish

2017-01-01

Last updated by the study team

2019-03-01

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The patient or patient's legally-authorized representative agrees to participate in this study by signing the Ethics Committee-approved informed consent form (ICF).
• Only XIENCE V stent(s) is/are implanted into the coronary vasculature during the index procedure.

You may not qualify if…

• The inability to obtain a signed ICF

Where it is running

• Abbott Vascular — Santa Clara, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.